CDD-2007

CDD-2007 is a selective and potent small-molecule inhibitor of casein kinase 2 (CK2) developed by the Baylor College of Medicine. Discovered using DNA-encoded chemical libraries (DELs) against the catalytic subunits of CK2, CDD-2007 exhibits low nanomolar cellular potency and good metabolic stability. It is designed to target CK2-mediated activation of estrogen receptor (ER) signaling, which is abnormally elevated in various cancers, including breast cancer. CDD-2007 has demonstrated efficacy in abolishing estrogen-induced gene programs in both wild-type and mutant (Y537S and D538G) ER-positive breast cancer cell lines. In preclinical models, it inhibits Ser129 phosphorylation of AKT, suppresses primary and metastatic tumor-derived organoid growth, and synergizes with the ER antagonist fulvestrant in ESR1-mutant patient-derived xenograft (PDX) models without significant toxicity.